These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15541959)

  • 1. Gene expression microarray technologies in the development of new therapeutic agents.
    Clarke PA; te Poele R; Workman P
    Eur J Cancer; 2004 Nov; 40(17):2560-91. PubMed ID: 15541959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification.
    Helleman J; Jansen MP; Berns EM
    Int J Gynecol Cancer; 2006; 16 Suppl 2():538-42. PubMed ID: 17010068
    [No Abstract]   [Full Text] [Related]  

  • 3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of oncology drug response markers using transcription profiling.
    Dracopoli NC
    Curr Mol Med; 2005 Feb; 5(1):103-10. PubMed ID: 15720273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery strategies: technologies to accelerate translation from target to drug.
    Workman P
    J Chemother; 2004 Nov; 16 Suppl 4():13-5. PubMed ID: 15688601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy and pharmacogenomic programs.
    Iqbal S; Lenz HJ
    Cancer; 2003 Apr; 97(8 Suppl):2076-82. PubMed ID: 12673699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically relevant cancer biomarkers and pharmacogenetic assays.
    Patel JN; Mandock K; McLeod HL
    J Oncol Pharm Pract; 2014 Feb; 20(1):65-72. PubMed ID: 23353710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials.
    Burczynski ME; Oestreicher JL; Cahilly MJ; Mounts DP; Whitley MZ; Speicher LA; Trepicchio WL
    Curr Mol Med; 2005 Feb; 5(1):83-102. PubMed ID: 15720272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription profiling of gene expression in drug discovery and development: the NCI experience.
    Sausville EA; Holbeck SL
    Eur J Cancer; 2004 Nov; 40(17):2544-9. PubMed ID: 15541957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.
    Clarke PA; te Poele R; Wooster R; Workman P
    Biochem Pharmacol; 2001 Nov; 62(10):1311-36. PubMed ID: 11709192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarrays to identify new therapeutic strategies for cancer.
    Sears C; Armstrong SA
    Adv Cancer Res; 2007; 96():51-74. PubMed ID: 17161676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving cancer therapeutics by molecular profiling.
    Corchero J; Fernández-Salguero PM
    Curr Drug Metab; 2005 Dec; 6(6):553-68. PubMed ID: 16379669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalised medicine for cancer: from drug development into clinical practice.
    Jain KK
    Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.
    Yap TA; Workman P
    Annu Rev Pharmacol Toxicol; 2012; 52():549-73. PubMed ID: 22235862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer target discovery using SAGE.
    Porter D; Polyak K
    Expert Opin Ther Targets; 2003 Dec; 7(6):759-69. PubMed ID: 14640911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of genomic and proteomic technologies on the development of new cancer drugs.
    Workman P
    Ann Oncol; 2002; 13 Suppl 4():115-24. PubMed ID: 12401677
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.
    Saba NF; Wilson M; Doho G; DaSilva J; Benjamin Isett R; Newman S; Chen ZG; Magliocca K; Rossi MR
    Head Neck Pathol; 2015 Jun; 9(2):223-35. PubMed ID: 25236499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
    Bild AH; Yao G; Chang JT; Wang Q; Potti A; Chasse D; Joshi MB; Harpole D; Lancaster JM; Berchuck A; Olson JA; Marks JR; Dressman HK; West M; Nevins JR
    Nature; 2006 Jan; 439(7074):353-7. PubMed ID: 16273092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of drug-targetable genes by defining modes of abnormality in gene expression.
    Park J; Lee J; Choi C
    Sci Rep; 2015 Sep; 5():13576. PubMed ID: 26336805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.